We continue to lead with science with our latest investments in cutting-edge technology to spearhead bioanalysis in drug development. At our bioanalytical lab, a fleet of brand-new SCIEX^® 7500+ units have been installed, which follows our other equally exciting high resolution instrument installations that came at the end of 2024.

Modern drug design calls for modern bioanalytical technology.

These state-of-the-art instruments will be applied to novel small molecule drug constructs, new drug formulation/delivery platforms, patient-centric sampling techniques, oligonucleotides/siRNA molecules, protein therapeutics, antibody-conjugated modalities, and a spectrum of biomarker applications. Our experts and modernized fleet of LC-MS instruments are poised to deliver unmatched sensitivity, capability, and flexibility across regulated bioanalysis applications.